These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26048686)

  • 21. [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].
    Doi H; Sakakibara R; Kishi M; Tsuyuzaki Y; Tateno F; Hirai S
    Rinsho Shinkeigaku; 2013; 53(11):1382-5. PubMed ID: 24291998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
    Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test.
    Unger MM; Möller JC; Mankel K; Schmittinger K; Eggert KM; Stamelou M; Stiasny-Kolster K; Bohne K; Bodden M; Mayer G; Oertel WH; Tebbe JJ
    Mov Disord; 2011 Dec; 26(14):2559-63. PubMed ID: 22147682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy.
    Perez-Lloret S; Rossi M; Cardinali DP; Merello M
    Int J Neurosci; 2010 Jan; 120(1):11-6. PubMed ID: 20128666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous dopaminergic delivery in Parkinson's disease.
    Antonini A; Ursino G; Calandrella D; Bernardi L; Plebani M
    J Neurol; 2010 Nov; 257(Suppl 2):S305-8. PubMed ID: 21080194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Madopar HBS in Parkinson patients with nocturnal akinesia.
    Jansen EN; Meerwaldt JD
    Clin Neurol Neurosurg; 1988; 90(1):35-9. PubMed ID: 3359732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
    Steiger MJ; Stocchi F; Carta A; Ruggieri S; Agnoli A; Quinn NP; Marsden CD
    Clin Neuropharmacol; 1991 Jun; 14(3):241-4. PubMed ID: 2070364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
    Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
    Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease.
    Arai E; Arai M; Uchiyama T; Higuchi Y; Aoyagi K; Yamanaka Y; Yamamoto T; Nagano O; Shiina A; Maruoka D; Matsumura T; Nakagawa T; Katsuno T; Imazeki F; Saeki N; Kuwabara S; Yokosuka O
    Brain; 2012 May; 135(Pt 5):1478-85. PubMed ID: 22522940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axial kinesthesia is impaired in Parkinson's disease: effects of levodopa.
    Wright WG; Gurfinkel VS; King LA; Nutt JG; Cordo PJ; Horak FB
    Exp Neurol; 2010 Sep; 225(1):202-9. PubMed ID: 20599976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease.
    Mollion H; Ventre-Dominey J; Dominey PF; Broussolle E
    Neuropsychologia; 2003; 41(11):1442-51. PubMed ID: 12849762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of early Parkinson's disease: levodopa rehabilitated.
    Vlaar A; Hovestadt A; van Laar T; Bloem BR
    Pract Neurol; 2011 Jun; 11(3):145-52. PubMed ID: 21551108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.